Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neoplasms, Germ Cell and Embryonal × Bevacizumab × Clear all

Phase

Phase 2 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 32 Glioblastoma 23 Carcinoma, Non-Small-Cell Lung 19 Ovarian Neoplasms 13 Brain Neoplasms 12 Pancreatic Neoplasms 11 Glioma 10 Carcinoma, Renal Cell 10 Breast Neoplasms 10 Neoplasms 9 Carcinoma, Hepatocellular 9 Neoplasm Metastasis 8 Colonic Neoplasms 8 Astrocytoma 8 Melanoma 7 Uterine Cervical Neoplasms 6 Rectal Neoplasms 6 Gliosarcoma 6 Lung Neoplasms 5 Fallopian Tube Neoplasms 5 Endometrial Neoplasms 5 Colorectal Cancer Metastatic 5 Advanced Solid Tumors 5 Stomach Neoplasms 4 Oligodendroglioma 4 Squamous Cell Carcinoma of Head and Neck 3 Small Cell Lung Carcinoma 3 Liver Neoplasms 3 Diffuse Intrinsic Pontine Glioma 3 Advanced Solid Tumor 3

Interventions

Cyclophosphamide 2 sodium thiosulfate 1 repotrectinib 1 pralsetinib 1 lutetium Lu 177 dotatate 1 fludarabine phosphate 1 fludarabine 1 Thrombopoietin 1 Plicamycin 1 Melphalan 1 Mannitol 1 ICE protocol 5 1 Etoposide 1 Drug Therapy 1 Cytosine Deaminase 1 Carboplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01966913 2019-02-19

TAXIFIII

Assistance Publique - Hôpitaux de Paris

Phase 1/2 Unknown

Neoplasms, Germ Cell and Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon ⚡